Skip to main content
letter
. 2020 Jun 17;34(8):2276–2278. doi: 10.1038/s41375-020-0907-9

Fig. 1. Ruxolitinib clears lung infiltration in SARS-CoV-2 induced ARDS.

Fig. 1

a Chest CT scans of the patient before transfer to the ICU reveals diffuse bilateral ground glass opacities, consolidations, and motion artifacts due to tachypnea. b After 11 days of treatment with ruxolitinib, markedly decreased ground glass opacities and motion artifacts, less pronounced regression of consolidations, and atelectasis.